PP
NBIX icon

PDT Partners’s Neurocrine Biosciences NBIX Stock Holding History

PDT Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,781
Closed -$3.79M – 572
2026
Q1 		$3.79M Hold
28,781
– – 0.22% 152
2025
Q4 		$4.08M Sell
28,781
-12,823
-31% -$1.86M 0.26% 136
2025
Q3 		$5.84M Sell
41,604
-1
-0% -$135 0.37% 73
2025
Q2 		$5.23M Buy
41,605
+23,200
+126% +$2.66M 0.3% 96
2025
Q1 		$2.04M Sell
18,405
-16,343
-47% -$2.07M 0.14% 247
2024
Q4 		$4.74M Buy
34,748
+19,848
+133% +$2.45M 0.42% 39
2024
Q3 		$1.72M Buy
+14,900
New +$2.04M 0.15% 249
2023
Q4 		– Sell
-9,306
Closed -$1.05M – 630
2023
Q3 		$1.05M Sell
9,306
-1,206
-11% -$127K 0.13% 273
2023
Q2 		$991K Buy
+10,512
New +$1.03M 0.14% 250
2022
Q4 		– Sell
-8,255
Closed -$877K – 803
2022
Q3 		$877K Buy
+8,255
New +$838K 0.13% 258
2015
Q4 		– Sell
-48,088
Closed -$1.91M – 749
2015
Q3 		$1.91M Sell
48,088
-400
-0.8% -$19.3K 0.04% 475
2015
Q2 		$2.32M Buy
48,488
+36,975
+321% +$1.57M 0.06% 380
2015
Q1 		$457K Buy
+11,513
New +$412K 0.01% 1048
2013
Q3 		– Sell
-23,788
Closed -$318K – 1639
2013
Q2 		$318K Buy
+23,788
New +$292K 0.01% 1238

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PDT Partners's NBIX Position: Q2 2026 in Review

PDT Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 28,781 shares — an estimated $3.79M sold.

PDT Partners first reported a position in NBIX in Q2 2013 and held it in 14 quarters. The position peaked at $5.84M in Q3 2025. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • PDT Partners reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • PDT Partners sold 28,781 Neurocrine Biosciences shares in Q2 2026, an estimated $3.79M.
  • PDT Partners first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 14 quarters.
  • PDT Partners's Neurocrine Biosciences position peaked at $5.84M in Q3 2025.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.